Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles

Neazar E Baghdadi; Benjamin P Burke; Tahani Alresheedi; Shubhanchi Nigam; Abdu Saeed; Farooq Almutairi; Juozas Domarkas; Abid Khan; Stephen J Archibald

doi:10.1039/d0dt02626c

Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles

Neazar E Baghdadi, Benjamin P Burke, Tahani Alresheedi, Shubhanchi Nigam, Abdu Saeed, Farooq Almutairi, Juozas Domarkas, Abid Khan, Stephen J Archibald

Pharmacy

Research output: Contribution to journal › Article › peer-review

Abstract

The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.

Original language	English
Journal	Dalton Transactions
DOIs	https://doi.org/10.1039/d0dt02626c
Publication status	Published - 27 Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/d0dt02626c

Cite this

@article{972f5a3e60da447b9771c119ce42bcc1,

title = "Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles",

abstract = "The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.",

author = "Baghdadi, {Neazar E} and Burke, {Benjamin P} and Tahani Alresheedi and Shubhanchi Nigam and Abdu Saeed and Farooq Almutairi and Juozas Domarkas and Abid Khan and Archibald, {Stephen J}",

year = "2021",

month = jan,

day = "27",

doi = "10.1039/d0dt02626c",

language = "English",

journal = "Dalton Transactions",

issn = "1477-9226",

publisher = "Royal Society of Chemistry",

}

TY - JOUR

T1 - Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles

AU - Baghdadi, Neazar E

AU - Burke, Benjamin P

AU - Alresheedi, Tahani

AU - Nigam, Shubhanchi

AU - Saeed, Abdu

AU - Almutairi, Farooq

AU - Domarkas, Juozas

AU - Khan, Abid

AU - Archibald, Stephen J

PY - 2021/1/27

Y1 - 2021/1/27

N2 - The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.

AB - The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.

U2 - 10.1039/d0dt02626c

DO - 10.1039/d0dt02626c

M3 - Article

C2 - 33502425

SN - 1477-9226

JO - Dalton Transactions

JF - Dalton Transactions

ER -

Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this